Unyvero A50 RQ BCU
Testing from positive blood cultures
Key Facts
About OpGen
OpGen's mission is to preserve the efficacy of antibiotics and improve patient outcomes by delivering rapid, precise diagnostic information to combat infectious diseases. Its core achievements include the FDA-cleared Acuitas AMR Gene Panel and the Unyvero multiplex PCR platform, which address critical needs in pneumonia, bloodstream, and urinary tract infections. The company's strategy integrates diagnostic testing with data analytics to support hospital antimicrobial stewardship and infection prevention programs, while its CapForce subsidiary represents a separate, non-core business initiative. OpGen faces the dual challenge of driving adoption in a competitive diagnostic market and achieving sustainable financial growth.
View full company profile